论文部分内容阅读
目的观察冠心病患者血浆脂联素水平的变化,探讨血浆脂联素水平与AMI院内主要不良心血管事件关系。方法选择冠心病患者151例,其中稳定型心绞痛47例,不稳定型心绞痛50例,急性心肌梗死(AMI)54例。选择50例健康体检者为正常对照组。采用ELISA法测定血浆脂联素浓度,比较不同类型冠心病患者及AMI院内有无发生主要不良心血管事件脂联素的均数。结果1血浆脂联素浓度(ug/ml):冠心病组(5.29±2.13)显著低于正常对照组(7.84±2.23,P<0.01);稳定型心绞痛组(7.17±1.73),与正常对照组比较差异无统计学意义(P>0.05);不稳定型心绞痛组(4.72±1.68)显著低于正常对照组和SA组(P<0.01);心肌梗死组(4.17±1.73)显著低于正常对照组和SA组(P<0.01)。2发生住院主要不良心血管事件(MACE)的AMI患者血浆脂联素(ug/ml)水平分析:MACE组血浆脂联素水平(2.73±1.16)明显低于非MACE组(4.83±1.55,P<0.01)。结论低脂联素水平可能是冠心病的发病因素之一,血浆脂联素水平可能有助于反映冠心病斑块的稳定性,也有助于AMI院内主要不良心血管事件预测。
Objective To observe the changes of plasma adiponectin level in patients with coronary heart disease and to explore the relationship between plasma adiponectin levels and major adverse cardiovascular events in hospital. Methods 151 patients with coronary heart disease were selected, including 47 patients with stable angina, 50 patients with unstable angina and 54 patients with acute myocardial infarction (AMI). Select 50 cases of healthy people as the normal control group. Plasma concentrations of adiponectin were measured by ELISA and the mean number of adiponectin was compared between patients with different types of coronary heart disease and those with or without AMI. Results Plasma adiponectin concentration (ug / ml): Coronary heart disease group (5.29 ± 2.13) was significantly lower than that of the normal control group (7.84 ± 2.23, P <0.01), and stable angina group (7.17 ± 1.73) Group (4.72 ± 1.68) was significantly lower than that of normal control group and SA group (P <0.01); myocardial infarction group (4.17 ± 1.73) was significantly lower than normal group (P> 0.05) Control group and SA group (P <0.01). Plasma levels of adiponectin (ug / ml) in patients with major adverse cardiovascular events (MACE) in hospital: Plasma adiponectin levels in MACE group (2.73 ± 1.16) were significantly lower than those in non-MACE group (4.83 ± 1.55, P <0.01). Conclusions Low adiponectin level may be one of the risk factors for coronary heart disease. Plasma adiponectin level may help to reflect the stability of coronary heart disease plaque and also predict the main adverse cardiovascular events in AMI hospital.